Revolution Medicines announced that its Phase 3 RASolute 302 trial of daraxonrasib met primary and secondary endpoints in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE